Ironwood and Forest Labs took the stage at the Digestive Disease Week conference to spell out their promising Phase III data on linaclotide, Ironwood's closely-watched treatment for irritable bowel syndrome with constipation. The therapy achieved statistically significant results for the primary as well as all secondary endpoints. "The results of these trials suggest that linaclotide may provide an attractive option for millions of patients suffering from chronic constipation," said investigator Anthony Lembo, M.D. Ironwood release